cnb791 ht logo promo |

Introducing the new PhysioMimix Single-Organ Higher Throughput System

Learn more
CN Bio logo CN Bio logo CN Bio logo CN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • SLAS Europe 2023

      • SOT 2023

      • WORD 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      • Doctoral Researcher (Horizon Marie Curie Doctoral Network Project)

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio makes key senior appointments to support international commercial development

August 5, 2020 by CN Bio

Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales

Cambridge, UK, 05 August 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the appointments of James Craven as Chief Commercial Officer and Dr. Brian Manning as US Head of Sales. At the same time, Dr. Sarah Payne joins the Company as Product Marketing Manager. Following the completion of a $9 million USD funding round in February, the appointments will help drive CN Bio’s sales and business strategy, with a focus on further developing its US customer base, the Company’s key market.

James has over 20 years’ commercial experience within the life sciences sector and has a wealth of expertise in marketing laboratory instruments. James joins CN Bio from Brooks Life Sciences, where he developed and managed relationships with global pharmaceutical companies as Director of Market Strategy and Commercial Delivery. He has held senior management positions at TTP Labtech and Titian Software. As CN Bio’s Chief Commercial Officer, James will harness the Company’s 10 years of established expertise, to expand its visibility and drive sales of products and services, including the PhysioMimix® platform.

Brian has significant business development experience across the pharma and biotech industries in the US, Europe and Asia, including in his most recent role at InSphero, as Senior Director of Business Development. Prior, Brian has held key positions at Pfizer, DiscoverX, GenScript, and Cyclofluidic, where he was Vice President of Business Development in North America. In his new role as US Head of Sales, Brian will be responsible for cultivating CN Bio’s commercial and scientific relationships, including building out the Company’s US presence and extensive application support, internationally.

Sarah joins CN Bio as Product Marketing Manager, where she will harness her substantial experience in combined sales, product management and marketing to shape the Company’s expanding technology portfolio in all application areas. Sarah has previously held senior marketing roles at leading life science companies, including SPT Labtech, most recently, and GE Healthcare.

James Craven, Chief Commercial Officer, CN Bio, commented: “As an established and trusted cell culture company, already working with over eight of the top 20 pharma companies globally, I’m enthusiastic to be part of CN Bio’s team, to build its strategic partnerships and ensure we continue to provide the best support to researchers. Brian, Sarah and I have significant subject matter experience, all with strong scientific backgrounds, which is essential when joining such a credible team, driven by technical expertise and depth of knowledge.” 

Dr. Brian Manning, US Head of Sales, CN Bio, said: “Following the Company’s recent successful fundraising round, CN Bio is taking all opportunities to strengthen its position in the US, and support our customer base, internationally. In doing so, we can meet the growing demand for innovative organ-on-chip systems, in order to enhance the development of tomorrow’s medicines.”

Dr. Sarah Payne, Product Marketing Manager, CN Bio, commented: “It is exciting to be joining CN Bio at this pivotal stage of growth. Over the past ten years, the Company has honed its technically advanced organ-on-chip platforms and services to deliver high quality human-relevant data that can be relied upon. In my new role I look forward to promoting widespread awareness for CN Bio’s innovative products and services within the life sciences. With an urgent market need for new in vitro tools that better predict clinical outcomes, it is a privilege to be working for a company whose potential to make a difference is so great.” 

For more information about CN Bio, please visit: https://cn-bio.com/

Category iconPress releases

Primary Sidebar

Other recent news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023
  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SOT 2023 March 19-23, 2023

WORD 2023 March 22, 2022